NY -- Standard&Poor's CreditWire 11/16/98 -- Standard&Poor's today affirmed its triple-'A' corporate credit, senior unsecured debt, and bank loan ratings, preliminary triple-'A' shelf debt rating, and its 'A-1'-plus commercial paper rating for Bristol-Myers Squibb Co. The outlook remains stable. The ratings continue to reflect Bristol-Myers' position as one of the world's largest pharmaceutical firms, the company's diverse and growing revenue base, and its solid financial position, which endures despite the impact of breast implant litigation. Bristol-Myers' pharmaceutical operations, which account for about 60% of total sales, anchor a broad business portfolio. The company's best-selling product, Pravachol, a heart attack and stroke prevention drug, continues to post solid sales gains in a highly competitive segment. The company's
